Cargando…

Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study

BACKGROUND: The PCSK9 antibody alirocumab (75 mg every 2 weeks; Q2W) as monotherapy reduced low‐density lipoprotein‐cholesterol (LDL‐C) levels by 47%. Because the option of a monthly dosing regimen is convenient, ODYSSEY CHOICE II evaluated alirocumab 150 mg Q4W in patients with inadequately control...

Descripción completa

Detalles Bibliográficos
Autores principales: Stroes, Erik, Guyton, John R., Lepor, Norman, Civeira, Fernando, Gaudet, Daniel, Watts, Gerald F., Baccara‐Dinet, Marie T., Lecorps, Guillaume, Manvelian, Garen, Farnier, Michel, Kostner, K., Lehman, S., Descamps, O., Gheyle, L., Mathieu, C., Bergeron, J., Elliott, T., Girard, G., Gupta, A., Hoag, G., Hove, J., Jeppesen, J., Kjærulf, J.H., Klarlund, K., Thomsen, K.K., Basart, D.C.G., Kooy, A., Liem, A., Swart, H., Troquay, R., Van Het Hof‐Wiersma, J, Viergever, P., Visseren, F., Doughty, R.N., Scott, R., Calvo, C., Díaz‐Díaz, J.L., Fuentes, F., Gil‐Extremera, B., Jericó, C., Matas Pericas, L., Mediavilla Garcia, J.D., Bolster, D.E., Koren, M., El Shahawy, M., Vardi, G., Weinstein, D., Zuzarte, K., Ginsberg, Henry, Robinson, Jennifer G., Rader, Daniel J., Cannon, Christopher P., Colhoun, Helen, Kastelein, John J.P., Huo, Yong, Olsson, Anders, Waters, David, Larrey, Dominique, Rosenson, Robert S., Patriarca, Peter A., Molenberghs, Geert, Tricoci, Pierluigi, Mahaffey, Kenneth W., Lopes, Renato D., Shah, Bimal R., Mehta, Rajendra H., Roe, Matthew T., Eapen, Zubin, Armaganijan, Luciana, Bertolami, Adriana, Leonardi, Sergio, Kolls, Bradley J., Jordan, J. Dedrick, Ducrocq, Grégory, Puymirat, Etienne, Mathews, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079013/
https://www.ncbi.nlm.nih.gov/pubmed/27625344
http://dx.doi.org/10.1161/JAHA.116.003421